Table 3.
Status of Peroxiredoxin Isoforms in Leukemia
| Prx isoform | Status in leukemia | Reference |
|---|---|---|
| I | • Increased, binds to c-Abl-inhibiting tyrosine kinase activity and cytotoxic events in vivo | (211, 256) |
| • mRNA downregulated in AML patient samples | (3) | |
| II | • High protein expression in AML patient samples | (149) |
| • Epigenetically silenced tumor suppressor gene in AML (low expression correlated with poorer prognosis) | (3) | |
| III | • High expression in APL cells expressing c-myc | (252) |
| • Identified in CML as a potential marker for response to imatinib | (86) | |
| IV | • Epigenetically downregulated in APL patient samples | (190) |
| • Potential translocation partner for the AML1 gene in AML | (275) | |
| V | • Significantly decreased mRNA expression in AML patient samples | (3) |
| VI | • No association with leukemia noted | — |